Practical Randomized Controlled Trial of Neixiao Ruanmai Decoction in Treating Carotid Atherosclerosis Plaque with Different Courses

Dongzhimen Hospital, Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with carotid atherosclerotic plaque diagnosed by color Doppler ultrasound;
•2. Patients aged from 40 to 65, regardless of gender;
•3. Patients with lumen stenosis less than 70%;
•4. Patients who can take medicine for a long time;
•5. Patients with informed consent and those who signed the informed consent.

•1. Patients with acute cardiovascular and cerebrovascular diseases;
•2. Patients with previous history of cerebral hemorrhage;
•3. Patients with active ulcer and bleeding tendency, long-term use of anticoagulant drugs (such as warfarin);
•4. Patients with severe arrhythmia, atrial fibrillation and heart failure;
•5. Patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system and respiratory system, whose liver function is more than 1.5 times higher than the upper limit of normal value, and Cr is higher than the normal value;
•6. Pregnant or lactating women, women with pregnancy plans in the near future;
•7. Patients with allergic constitution;
•8. Patients using dual antiplatelet drugs;
•9. Any other life-threatening or serious disease that cannot be treated for 12 months will affect the evaluation results;
•10. Other diseases or mental disorders that researchers believe may limit efficacy evaluation or patient follow-up;
•11. Patients who have participated in clinical trials of other drugs in recent 4 weeks.

发起方

Dongzhimen Hospital, Beijing University of Chinese Medicine